Lindenauer Peter K, Fitzgerald Janice, Hoople Nancy, Benjamin Evan M
Division of Healthcare Quality, Baystate Medical Center, Springfield, Mass, USA.
Arch Intern Med. 2004 Apr 12;164(7):762-6. doi: 10.1001/archinte.164.7.762.
Among selected patients undergoing major noncardiac surgery, beta-adrenergic blockade has been shown to reduce the risk for postoperative cardiac complications and mortality. We sought to determine how often postoperative MI might be considered preventable through appropriate use of these medications.
We reviewed the medical records of patients who developed a postoperative MI between January 1, 1998, and October 31, 2001, at Baystate Medical Center, a 570-bed community-based teaching hospital in Springfield, Mass. We calculated a Revised Cardiac Risk Index score and used criteria from previous randomized trials to determine whether patients would have been candidates for perioperative beta-adrenergic blockade. Postoperative MI was considered potentially preventable if the patient appeared to have been an ideal candidate for beta-blocker therapy but did not receive it before the infarction. We compared the mortality of ideal candidates who did and did not receive beta-blockers before their infarction using multivariable logistic regression.
Seventy (97%) of the 72 patients who developed postoperative MI could have been identified as being at increased risk for cardiac complications, and 58 (81%) appeared to be ideal perioperative beta-blocker candidates. Thirty ideal candidates (52%) were treated with beta-blockers before the development of the infarction. Among ideal candidates, treatment with a beta-blocker before infarction was associated with an odds ratio of in-hospital mortality of 0.19 (95% confidence interval, 0.04-0.87).
A large percentage of the postoperative MIs at our institution might have been prevented if a beta-blocker had been administered to all ideal candidates around the time of surgery. Use of beta-blockers before infarction may reduces overall mortality, even among patients who go on to develop this complication.
在接受大型非心脏手术的特定患者中,β受体阻滞剂已被证明可降低术后心脏并发症和死亡率的风险。我们试图确定通过合理使用这些药物,术后心肌梗死(MI)有多少情况可能被认为是可预防的。
我们回顾了1998年1月1日至2001年10月31日期间在贝斯州医疗中心发生术后MI的患者的病历,该中心是马萨诸塞州斯普林菲尔德一家拥有570张床位的社区教学医院。我们计算了修订的心脏风险指数评分,并使用先前随机试验的标准来确定患者是否会成为围手术期β受体阻滞剂治疗的候选人。如果患者似乎是β受体阻滞剂治疗的理想候选人,但在梗死前未接受治疗,则术后MI被认为可能是可预防的。我们使用多变量逻辑回归比较了梗死前接受和未接受β受体阻滞剂的理想候选人的死亡率。
72例发生术后MI的患者中有70例(97%)可被确定为心脏并发症风险增加,58例(81%)似乎是围手术期β受体阻滞剂的理想候选人。30例理想候选人(52%)在梗死发生前接受了β受体阻滞剂治疗。在理想候选人中,梗死前接受β受体阻滞剂治疗与院内死亡率的比值比为0.19(95%置信区间,0.04 - 0.87)。
如果在手术前后对所有理想候选人使用β受体阻滞剂,我们机构中很大一部分术后MI可能会被预防。即使在发生这种并发症的患者中,梗死前使用β受体阻滞剂也可能降低总体死亡率。